Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Published:2017-12-08 Issue:6 Volume:110 Page:628-637
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Gluz Oleg¹²³,Nitz Ulrike¹²,Liedtke Cornelia⁴,Christgen Matthias⁵,Grischke Eva-Maria⁶,Forstbauer Helmut⁷,Braun Michael⁸,Warm Mathias⁹,Hackmann John¹⁰,Uleer Christoph¹¹,Aktas Bahriye¹²¹³,Schumacher Claudia¹⁴,Bangemann Nikola¹⁵,Lindner Christoph¹⁵¹⁶,Kuemmel Sherko¹⁷,Clemens Michael¹⁸,Potenberg Jochem¹⁹,Staib Peter²⁰,Kohls Andreas²¹,von Schumann Raquel²,Kates Ronald¹,Kates Ronald,Schumacher Johannes²²,Wuerstlein Rachel²³,Kreipe Hans Heinrich⁵,Harbeck Nadia¹²³

Affiliation:

1. Moenchengladabach, West German Study Group

2. Moenchengladbach, Breast Center Niederrhein, Evangelical Hospital Johanniter Bethesda

3. University Clinics Cologne

4. Department of Gynecology and Obstetrics, University Clinics Schleswig-Holstein/Campus Luebeck

5. Institute of Pathology, Medical School Hannover

6. Department of Gynecology and Obstetrics, University Clinics Tuebingen

7. Oncology Practice Network Troisdorf

8. Breast Center, Rotkreuz Clinics Munich

9. Breast Center, City Hospital of Cologne Holweide

10. Breast Center, Marien-Hospital Witten

11. Gynecologic Oncologic Practice Hildesheim

12. Department of Gynecology and Obstetrics, University Clinics Essen

13. Department of Gynecology, University Hospital Leipzig

14. Breast Center, St. Elisabeth Hospital Cologne

15. Clinic of Gynecology, Charité University Clinics Berlin

16. Department of Gynecology and Obstetrics, Agaplesion Diakonie Clinic

17. Clinics Essen-Mitte, Breast Center

18. Department of Oncology, Clinics Mutterhaus Trier

19. Department of Oncology, Evangelical Waldkrankenhaus Berlin

20. Department of Oncology, St. Antonius Hospital

21. Department of Gynecology and Obstetrics, Evangelical Hospital Ludwigsfelde

22. Statitistics, Palleos Healthcare

23. Breast Center, University of Munich (LMU) and CCCLMU, Munich, Germany

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/6/628/25041877/djx258.pdf

Reference56 articles.

1. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol.,2008

2. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis;Cortazar;Lancet.,2014

3. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol.,2012

4. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto;GBG 69): A randomised, phase 3 trial;Untch;Lancet Oncol.,2016

5. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance);Sikov;J Clin Oncol.,2015

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review on the State of the Art of Breast Cancers in Italy;Current Medicinal Chemistry;2024-06

2. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial;eClinicalMedicine;2024-05

3. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE);ESMO Open;2024-05

4. Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung;Die Gynäkologie;2024-04-18

5. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy;Clinical Cancer Research;2024-03-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3